Amanta Healthcare: Director's kin enhances stake by ₹15 Lakh

Acquired 15,675 equity shares for ₹15,01,041.13 between March 19-24, 2026.

Reader Takeaway: Insider purchase by promoter's kin adds minor stake; stock faces pressure from subdued growth outlook.

What just happened (today’s filing)

Amanta Healthcare Limited has disclosed an open market purchase of 15,675 equity shares by Ms. Dympal Jain.

Ms. Jain is an immediate relative of Director Shri Nitin Jain.

The transaction, valued at ₹15.01 lakh, took place between March 19 and March 24, 2026.

This disclosure is a compliance measure under SEBI's insider trading regulations.

Why this matters

While the value is modest, any purchase by an insider or their relative is often seen as a signal of confidence in the company's future prospects.

It provides a small data point for investors tracking promoter group activity.

The backstory (grounded)

Amanta Healthcare is a pharmaceutical manufacturer focusing on sterile liquid products like large volume parenterals (LVPs) and small volume parenterals (SVPs), using advanced ABFS and ISBM technologies.

The company completed its IPO in September 2025 and is using proceeds for capacity expansion of its SVP and SteriPort lines.

Financially, Amanta reported record quarterly net sales of ₹74.49 crore in Q3 FY26 and significant PAT growth for the nine months ended December 2025 (₹10.75 crore, +73.88% YoY).

However, its long-term sales growth remains subdued, with a negative 5-year CAGR of -2.00%.

This divergence in performance and market sentiment has led to the stock hitting a 52-week low of ₹93.1 on March 23, 2026.

Promoter holding has remained stable around 63.56%, while mutual fund holdings increased in the December 2025 quarter.

What changes now

• Ms. Dympal Jain's equity holding has increased to 15,676 shares.
• Her stake now represents 0.04% of Amanta Healthcare's total equity.
• The overall shareholding pattern sees a minor adjustment within the promoter group.

Risks to watch

While this specific transaction is routine, investors should monitor the company's ability to translate recent profit growth into sustainable revenue expansion.

The subdued long-term sales growth remains a key pressure point for the stock.

Peer comparison

Amanta Healthcare operates in the competitive Indian pharmaceutical sector, which includes major players like Lupin Ltd. and Cipla Ltd., alongside API specialists such as Divi's Laboratories Ltd.

These peers often exhibit different growth trajectories and market valuations, highlighting the varied landscape within the sector.

Context metrics (time-bound)

• As of March 2026, Ms. Dympal Jain's direct shareholding is 15,676 equity shares, constituting 0.04% of the total equity.
• The acquisition occurred during the period of March 19, 2026 – March 24, 2026.

What to track next

• Any further disclosures of share acquisitions or disposals by promoters or key management personnel.
• The company's ability to leverage its capacity expansions and achieve revenue growth targets.
• The stock's reaction to this insider purchase and broader market sentiment.
• Performance of the newly installed solar plant on operational costs.